ArticlePlastic and reconstructive surgery. Global open2025
Pilot Study: Blue Light Photobiomodulation for the Treatment of Complicated Wounds in Breast Surgery.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Systemic and locoregional therapies for cutaneous metastases from breast cancer: state of art and new frontiers in treatment approach.Therapeutic advances in medical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Blue light photobiomodulation has demonstrated efficacy in accelerating the healing process of chronic ulcers and various dermatologic conditions. Yet, its application in enhancing the healing of complicated postsurgical breast wounds, particularly in reconstructive surgery, remains unexplored. Methods: This pilot study included female patients who developed complicated wounds after reconstructive breast surgery at our institution between March 2022 and September 2023. All patients were treated with blue light therapy (EmoLED) in addition to standard wound care. We examined healing times, the number of EmoLED sessions required, and complication severity. Results: Among 27 female patients (median age 54 y), 74.1% underwent mastectomy with implant-based reconstruction, whereas the remaining patients underwent contralateral second-stage reduction mammaplasty. Over a 19-month median follow-up, 35 complications were recorded: 18 skin necroses, 9 partial nipple-areolar complex necroses, and 8 wound dehiscences. The median number of EmoLED sessions required was 5, typically administered weekly. A higher body mass index ( Conclusions: The use of blue light therapy accelerated and optimized the healing process in complicated postsurgical breast wounds. Larger prospective studies are warranted to further validate these findings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.